Publications by authors named "Turner Schwartz"
Precis: Perspectives and practice patterns regarding perioperative anticoagulation management and minimally invasive glaucoma surgery were queried among surgeons of American Glaucoma Society. Management varied based on surgeon preference and type of procedure performed.
Purpose: The purpose of this study was to characterize anticoagulation and antiplatelet practice patterns for minimally invasive glaucoma surgery (MIGS) in the perioperative period.
Article Synopsis
- A case report details a 62-year-old woman with multiple myeloma who developed eye issues after starting teclistamab, a new treatment for her condition.
- She experienced right eye pain and reduced vision, leading to the diagnosis of sclerouveitis with hypopyon shortly after beginning the medication.
- Treatment involved antibiotics and steroids; her condition improved, suggesting that teclistamab might be related to her eye complications based on a probable adverse drug reaction assessment.
Glaucomatous neurodegeneration, a blinding disease affecting millions worldwide, has a need for the exploration of new and effective therapies. Previously, the glucagon-like peptide-1 receptor (GLP-1R) agonist NLY01 was shown to reduce microglia/macrophage activation, rescuing retinal ganglion cells after IOP elevation in an animal model of glaucoma. GLP-1R agonist use is also associated with a reduced risk for glaucoma in patients with diabetes.
View Article and Find Full Text PDFRetinal inflammation underlies multiple prevalent ocular and neurological diseases. Similar inflammatory processes are observed in glaucomatous optic neuropathy, age-related macular degeneration, retinitis pigmentosa, posterior uveitis, Alzheimer's disease, and Parkinson's disease. In particular, human and animal studies have demonstrated the important role microglia/macrophages play in initiating and maintaining a pro-inflammatory environment in degenerative processes impacting vision.
View Article and Find Full Text PDF